Danny Thompson


Nigel Coffey

Formerly of Shire Pharmaceuticals and Takeda

Call Nigel Coffey a change agent, or call him a serial innovator. Everywhere Nigel takes on a new leadership challenge, he executes a program that adds tangible bottom-line value to his new organization. Starting with industry benchmarking, following with an audit of payments to suppliers to identify root cause issues and control weaknesses, and progressing through a systematic program of automation, Nigel has succeeded time and time again in moving each company to world-class procure-to-pay processes and technologies.


In his career Nigel has held senior business service, finance and transformation roles at Pfizer, PepsiCo, Shire Pharmaceuticals/Takeda and now Alnylam Pharmaceuticals. As the Head of Finance operations at this rapidly-growing biotech, he’s helping optimize the processes to help this company produce leading-edge therapies based on the latest RNA interference science.


Hear Nigel and Danny Thompson, SVP of Market & Product Strategy at apexanalytix, as they discuss:


• How fresh industry benchmarking information on finance and procure-to-pay best practices can be leveraged to establish goals and inform business cases for talent and technology.

• The one-two punch of recovery audit: improving AP profitability and uncovering weak controls, supplier issues and root causes of overpayments.

• Optimising prior to automating: why improving and rationalising end-to-end processes, policies, procedures and controls is critical before selecting and implementing technology.


Featuring: The latest 2021 benchmarking results from apexanalytix’s P2PKey Practices Benchmarking survey. The newest P2P survey data and insights from top tier global companies.


Ready to roar?

Fill out our contact form and we will be in touch shortly to discuss how we can help.